A Study of Subcutaneous Injection in Healthy Participants
Completed · Not applicable · NCT06516913
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $152,825
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Harvard Apparatus syringe pump (device)
- Dates
- Started 2024-07-22; completion 2024-09-07
- Results posted
- Not yet
This is a device feasibility study designed to evaluate the practicality of delivering a high-viscosity solution subcutaneously using various injection parameters, including volume, rate, and needle length. The goal is to assess the usability and operational performance of a delivery setup (Havard apparatus syringe pump and related components) to inform design requirements for future large-volume injection devices. No active drug is administered in this study, and no health outcomes are being evaluated. The study duration is approximately 40 days, including screening, injection assessments, and follow-up.
From ClinicalTrials.gov, last updated 2025-08-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $152,825 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $152,825
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.